A Novel Arenaviral Immunotherapy for Targeting Multiple Mutated KRAS Epitopes
Time: 1:30 pm
day: Day One Track C
Details:
- Introduction to HOOKIPAs Platform for induction of tumor specific CD8+ T-cell responses
- Overview on key clinical data demonstrating induction of unprecedented tumor specific CD8+ responses in humans
- Overview and preclinical validation of HOOKIPA’s HB700 program targeting most frequent KRas mutations in pancreatic cancer, colorectal cancer and lung adenocarcinoma
